MOR107

MOR107 is a novel lanthipeptide from our proprietary technology platform that has been studied in phase 1 clinical development

MOR107 is a lanthipeptide based on the proprietary technology platform of our subsidiary Lanthio Pharma B.V. and it is a selective agonist of the angiotensin II receptor type 2 (AT2-R). Lanthipeptides are a novel class of therapeutics with potential high target molecule selectivity and high in vivo stability. Lanthipeptides can be designed to combine agonistic or antagonistic activity with low toxicity risk. Especially highly selective lanthipeptide agonists are expected to open up new therapeutic applications with potential in indications that are not usually targeted with antibodies. , MOR107 is the first lanthipeptide in MorphoSys’s clinical pipeline. Based on initial anti-tumor data, MOR107 is currently in pre-clinical investigation with a focus on oncology indications.

 

Background on Lanthipeptides

With the acquisition of Lanthio Pharma B.V. in 2015, MorphoSys gained full access to Lanthio Pharma’s proprietary LanthioPep technology. This technology may be used to generate novel peptide products with therapeutic potential. Scientists from MorphoSys and Lanthio Pharma have developed a proprietary platform which permits phage display of lanthipeptides. This platform synergistically combines MorphoSys’s expertise in phage display and library diversification of monoclonal antibodies with Lanthio Pharma’s knowledge of lanthipeptide biosynthesis.
As natural ligands to many targets, peptides may have agonistic or antagonistic activity with low toxicity risk and might be applied to disease targets, where small molecules or antibody-based products cannot be used. Our lanthipeptides offer the potential to overcome these problems and make it possible to discover highly target-selective peptides, which only bind and activate one specific target subtype.
 

 

Mode of action and potential therapeutic field

MOR107 has been designed as a selective agonist of the angiotensin II type 2 receptor (AT2-R). AT2-R signaling has been related to various cellular processes including muscle cell proliferation, oxidative stress, inflammation, fibrosis, artheriosclerosis, vascular remodeling, cardiac hypertrophy and oncology.

Based on pre-clinical initial anti-tumor data, MOR107 is currently in pre-clinical investigation with a focus on oncology indications. A decision regarding the clinical indication regarding potential further testing of MOR107 has not been taken yet.

 

Clinical Studies

In early 2017, we initiated a first-in-human phase 1 clinical study of MOR107 in healthy male volunteers. The goal of the single-center randomized, double-blind, placebo-controlled study was to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered single ascending doses of MOR107. In May 2017, the first part of the clinical study in healthy volunteers was completed, and the study was terminated.
Based on pre-clinical initial anti-tumor data, MOR107 is currently in pre-clinical investigation with a focus on oncology indications.